2SX Stock Overview
scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
scPharmaceuticals Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.50 |
| 52 Week High | US$11.20 |
| 52 Week Low | US$4.00 |
| Beta | 0.045 |
| 1 Month Change | 1.81% |
| 3 Month Change | -3.43% |
| 1 Year Change | -59.82% |
| 3 Year Change | -3.02% |
| 5 Year Change | 45.02% |
| Change since IPO | -51.25% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2SX | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 8.7% | 3.8% | 1.9% |
| 1Y | -59.8% | -25.3% | 4.6% |
Return vs Industry: 2SX underperformed the German Pharmaceuticals industry which returned -25.9% over the past year.
Return vs Market: 2SX underperformed the German Market which returned 4.2% over the past year.
Price Volatility
| 2SX volatility | |
|---|---|
| 2SX Average Weekly Movement | 8.9% |
| Pharmaceuticals Industry Average Movement | 7.3% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 10.4% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 2SX has not had significant price volatility in the past 3 months.
Volatility Over Time: 2SX's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 136 | John Tucker | www.scpharmaceuticals.com |
scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX. The company’s product pipeline also includes SCP-111 (furosemide injection), an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home; and SCP-111 Autoinjector, an investigational single-entity, drug-device combination product candidate consisting of a prefilled syringe containing SCP-111, preloaded into a commercially available, fixed single dose, disposable, two step mechanical autoinjector.
scPharmaceuticals Inc. Fundamentals Summary
| 2SX fundamental statistics | |
|---|---|
| Market cap | €157.51m |
| Earnings (TTM) | -€51.06m |
| Revenue (TTM) | €12.66m |
12.4x
P/S Ratio-3.1x
P/E RatioIs 2SX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2SX income statement (TTM) | |
|---|---|
| Revenue | US$13.59m |
| Cost of Revenue | US$3.81m |
| Gross Profit | US$9.78m |
| Other Expenses | US$64.59m |
| Earnings | -US$54.81m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 14, 2024
| Earnings per share (EPS) | -1.52 |
| Gross Margin | 71.96% |
| Net Profit Margin | -403.22% |
| Debt/Equity Ratio | 104.3% |
How did 2SX perform over the long term?
See historical performance and comparison